[Correspondence] Adjuvant therapy in resectable gastric cancer—the CRITICS trial

Stomach cancer is among the most common cancers in the world, and surgery remains the key curative therapy for localised gastric cancer. To reduce the risk of relapse and improve survival, two landmark trials, INT01161 and MAGIC,2 established the role of postoperative chemoradiation (INT0116) and perioperative chemotherapy (MAGIC) in treatment of resectable gastric cancer.3 These two approaches became standard practice for contemporary treatment: patients are treated with surgery and perioperative chemotherapy or postoperative chemoradiation in different centres.

https://ift.tt/2MC4GbV